Amalia M. Issa, PhD, MPH, FCPP

Amalia M. Issa PhD, MPH, FCPP

Founding Director, Personalized Medicine & Targeted Therapeutics

Professor of Health Policy and Public Health
Professor of Pharmaceutical Sciences


BS (Concordia)

MS (McGill)

PhD (McGill)


Post-doctoral Fellowship (Harvard Medical School)

Research Interests

Personalized medicine; pharmacogenomics; pharmaceutical outcomes research and policy; pharmacoepidemiology


Amalia M. Issa, PhD, MPH, FCPP is a pharmacologist and internationally renowned scientist in the field of personalized genomic medicine (precision medicine). Dr. Issa was one of the first scientists to develop a new and unique area of health outcomes and translational research focused on pharmacogenomics and personalized genomic medicine applications, and how they will be translated and integrated into health care delivery and health systems. She founded one of the first centers on Personalized Medicine and Targeted Therapeutics focused on the translation of personalized medicine into clinical practice and health policy in 2001. She joined the University of the Sciences in 2011, and brought this center with her. This Center accomplishes its mission through state-of-the-art research, training programs, consultation to government agencies on public policy initiatives, and national and international collaborations. Dr. Issa leads and collaborates with an interdisciplinary team of scientists nationally and internationally who are actively engaged in research aimed at translating personalized genomic medicine research from the laboratory bench to the bedside and to the clinic, community, and policy. Dr. Issa has numerous publications in the peer-reviewed scientific literature on pharmacogenomics and personalized medicine as well as in pharmacoepidemiology, neuropharmacology and drug safety. She has served or is serving as the principal investigator on a number of funded projects and is a reviewer for several scientific journals and national and international granting agencies. Dr. Issa serves on editorial boards and in leadership positions in several national and international professional associations and has received many awards and honors for her work, including the 2013 University of the Sciences’ Founder’s Day Faculty Award of Merit given to the faculty member who “represents the innovative and entrepreneurial spirit of the University Founders, and who has engaged in research that results in new developments or innovations” and is a Fellow of the College of Physicians of Philadelphia, the oldest national medical society.

Selected Scholarly Activity

Issa, AM, Marchant GE, and Campos-Outcalt, D. Big data in the era of precision medicine: Big promise or big liability? Personalized Medicine, 13(4): 283-285, 2016.

Chaudhari V and Issa AM. Payer Decision Making for Novel Genomic Diagnostics for Precision Medicine International Society for Pharmacoeconomics and Outcomes Research. Washington, DC, May 21-26, 2016.

Patil, DS and Issa, AM. Factors affecting the adoption and use of gene expression profiling by oncologists in clinical practice. Personalized Medicine, 12(1): 33-42, 2015.

Issa, AM, Chaudhari, VS and Marchant, GE. The value of multigene predictors of clinical outcome in breast cancer: An analysis of the evidence. Exp Rev. Molecular Diagnostics, 15(2): 277-286, 2015.

Issa, AM. Ten years of personalizing medicine: How the incorporation of genomic information is changing practice and policy. Personalized Medicine 12(1): 1-3, 2015.

Schwartz E and Issa, AM. A National Survey of Pharmacists’ Roles in Clinical Pharmacogenomics: Assessment of Predictors. International Society for Pharmacoepidemiology Annual Meeting Boston, MA August 23-26, 2015

Issa, AM, Bartlett-Esquilant G, Dawes M and Marchant GE. Personalized medicine in the era of big data.  Value in Health, 17: 2014.

Bartlett, G, Rahimzadeh, V, Longo, C, Orlando, LA, Dawes, M, Lachaine, J, Bochud, M, Paccaud, F, Bergman, H, Crimi, L, and Issa, AM. The future of genomic testing in primary care: the changing face of personalized medicine. Personalized Medicine 11(5), 477–486, 2014.

Cuffe, S, Hon, H, Qiu, X, Tobros, K, Wong CKA, De Souza B, McFarlane G,  Masroor S, Azad, AK, Hasani E, Rozanec N, Leighl N, Alibhai S, Xu W, Issa, AM, Liu, G.  Cancer Patients’ Understanding, Acceptance and Willingness-to-Pay for Pharmacogenomic Testing, Pharmacogenomics and Genomics, 24(7): 348-355, 2014.

Issa, AM, Tufail, W, Atehortua, NA, and McKeever, J. A national study of breast and colorectal cancer patients’ decision making for novel personalized medicine genomic diagnostics. Personalized Medicine, 10(3): 245-256, 2013.

Yang, M, Patil, DS, Tufail, W, Issa, AM. The quality of economic studies of cancer pharmacogenomics: A quantitative appraisal of the evidence. Exp Rev Pharmacoeconomics and Outcomes Research 13(5): 597-611, 2013.

Yang, M, Rajan, S, and Issa, AM. Cost effectiveness of gene expression profiling for early stage breast cancer. Cancer. 118(20): 5163–5170, 2012 doi: 10.1002/cncr.27443, PMID:22359236.

Issa, AM, Hutchinson JF, Tufail W, Fletcher E, Ajike R, and Tenorio J. Provision of Personalized Genomic Diagnostic Technologies for Breast and Colorectal Cancer: An Analysis of Patient Needs, Expectations and Priorities Personalized Medicine 8(4): 401-411, 2011.

Joly Y., Koutrikas G., Tassé AM., Issa AM., Carleton B., Hayden M., Rieder MJ.,Ramos- Paque E. and Avard D. Regulatory approval for new pharmacogenomics tests: A comparative overview. Food and Drug Law Journal 66 (1): 1-24, 2011.

Arar, N., Knight SJ, Modell SM and Issa, AM. The Genome-based knowledge management in cycles (G-KNOMIC) model: A complex adaptive systems framework for implementation of genomic applications. Pers. Med. 8(2): 191-205, 2011.

McKibben L, Boone DJ , Marchibroda J and. Issa AM, A novel transformation model for personalized medicine laboratory systems Pers. Med, 7(1): 87-94, 2010.

Contact Information

Mailing address: University of Sciences
600 South 43rd Street
Philadelphia, PA 19104-4495
Office Phone: 215-596-7033

a [dot] issa [at] usciences [dot] edu